Research paper
The effect of magnesium supplementation on vascular calcification in chronic kidney disease—a randomised clinical trial (MAGiCAL-CKD): essential study design and rationale
Study answer
What this study found
This paper presents the trial design and rationale rather than efficacy results. The primary endpoint is the difference in change in coronary artery calcification score from week 0 to week 52 between magnesium and placebo, measured by CT using the Agatston method. Secondary endpoints include cf-PWV, PWA, BMD, mineral metabolism markers, eGFR decline, major adverse cardiovascular events, all-cause and cardiovascular mortality, adverse events, and ESRD. The authors conclude that the study will test whether increasing magnesium uptake can slow vascular calcification progression in predialysis…
- Study & population
- Randomized, placebo-controlled clinical trial in 250 adults with predialysis chronic kidney disease stage 3b-4.
- Intervention
- Oral slow-release magnesium hydroxide (Mablet 360 mg) was tested at a daily dose of 30 mmol elemental magnesium, given as 2 tablets per day for 52 weeks, compared with placebo.
- Key limitation
- No clinical efficacy results are reported in this design paper.
View source
Open PDFOriginal abstract
Introduction Chronic kidney disease (CKD) is associated with an increased risk of cardiovascular disease and mortality, which is thought to be caused by increased propensity towards vascular calcification (VC). Magnesium (Mg) inhibits phosphate-induc…